<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063022</url>
  </required_header>
  <id_info>
    <org_study_id>ISG/AIEOP EW-1</org_study_id>
    <nct_id>NCT02063022</nct_id>
  </id_info>
  <brief_title>Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma</brief_title>
  <acronym>EW-1</acronym>
  <official_title>Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled, randomized phase III study, with the intent of optimizing the treatment of not
      metastatic Ewing Sarcoma. The patients will be randomized into 2 arms: standard treatment vs
      intensive treatment. Both arms will receive an induction treatment followed by surgery
      (wherever is possible) and/or radiotherapy. The maintenance treatment will be different on
      the basis of the response to the induction treatment (good or poor)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients with non metastatic Ewing's Sarcoma will be randomized into 2 different
      arms: standard treatment arm A (based on the ISG/SSG III protocol) or into the experimental
      arm B(chemotherapy with dose intensification and shorter length of treatment).

      Both arm will receive an induction treatment with higher dose intensity of doxorubicin and
      ifosfamide in Arm B.

      After the induction treatment all the patient will undergo to local treatment (surgery and/or
      radiotherapy)that will be followed by a maintenance therapy.

      The maintenance therapy will be different for both arms and, within each arm, on the basis of
      the response (histologically evaluated) of the pre-local treatment therapy.

      Maintenance for Arm A: Poor responders will undergo to stem cells apheresis and their
      reinfusion after treatment with high doses of Busulfan and Melphalan 25 weeks.

      Good responders will receive a 6 drugs maintenance treatment for 37 weeks (as per standard
      ISG/SSG III protocol)

      Maintenance for Arm B: Poor responders will undergo to stem cells apheresis and their
      reinfusion after an intensified treatment with high doses of Busulfan and Melphalan (25
      weeks).

      Good responders will receive a maintenance treatment for 25 weeks

      The primary aim of the study is to assess the Event Free Survival (EFS) that is expected to
      be similar in both arms

      The secondary objectives are:

      To assess if the induction treatment in Arm B is able to increase the percentage of good
      responders compared to those who receive standard treatment.

      To assess the toxicity and the Quality of Life related to the chemotherapy treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The EFS (event defined as Progressive Disease , onset of local relapse and/or metastasis, death due to chemotherapy toxicity or for other causes) will be calculated from the first treatment day up to the event onset or to last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>expected average 3 years</time_frame>
    <description>The DFS will be calculated from the day that the patient will be free from disease (surgery date and/or radiotherapy completion) up to the date of progression disease or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis Free Survival</measure>
    <time_frame>expected average 2 years</time_frame>
    <description>The Metastasis free Survival will be evaluated from the time of disease free (surgery performed and/or radiotherapy completed) to the onset of distance metastasis or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>expected average 5 years</time_frame>
    <description>The OS will be evaluated for the start treatment day to the day of death (for any causes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Ewing's Sarcoma</condition>
  <arm_group>
    <arm_group_label>Standard treatment (as per ISG SSG III protocol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment for non metastatic Ewing's Sarcoma (as defined by the ISG/SSG III protocol).
It is based on a 6 drugs pre-local treatment (Vincristin, dactinomycin, cyclophosphamide,ifosfamide,etoposide and doxorubicin) followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensified treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose intense treatment for non metastatic Ewing's Sarcoma It is based on a 3 drug pre-local treatment (Vincristin, ifosfamide and doxorubicin)followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment (as per protocol ISG SSG III)</intervention_name>
    <description>Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)</description>
    <arm_group_label>Standard treatment (as per ISG SSG III protocol)</arm_group_label>
    <other_name>Vincristine</other_name>
    <other_name>Dactinomycin</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Ifosfamide</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Busulfan</other_name>
    <other_name>Melphalan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensified chemotherapy</intervention_name>
    <description>Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks
Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment
Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)</description>
    <arm_group_label>Intensified treatment</arm_group_label>
    <other_name>Vincristine,</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Ifosfamide</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Busulfan</other_name>
    <other_name>Melphalan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Ewing Sarcoma or PNET diagnosis centrally confirmed

          -  Age â‰¤ 40 years

          -  Absence of evident metastasis or lung met &lt; 0.5 cm Presence of skip metastasis in the
             bone compartment of the primary tumor is to be considered as local disease and not
             metastatic.

          -  Adeguate bone marrow, hepatic and renal function

          -  Left Ventricular Ejection Fraction &gt; 50%

          -  No primary Ewing Sarcoma treatments (both chemotherapy and/or radiotherapy)

          -  Voluntarily signed an informed consent form

          -  Radiological and histological documentation available for central review.

        Exclusion Criteria

          -  Presence of lung or extra-pulmonary lesions

          -  Bone Marrow involvement

          -  In case of chest disease: presence of plural effusion

          -  Elapsed time between histological diagnosis and chemotherapy start, more than 4 weeks

          -  Any medical contraindication to the use of the study drugs

          -  Any psychological or social conditions that can compromise the protocol compliance
             and/or follow-up

          -  Previous malignancies (excluded in situ cervix carcinoma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Ferrari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Italian Sarcoma Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Ferrari, MD</last_name>
    <phone>+390516366</phone>
    <phone_ext>4111</phone_ext>
    <email>stefano.ferrari@ior.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Piero Picci, MD</last_name>
    <phone>+390516366</phone>
    <phone_ext>6759</phone_ext>
    <email>piero.picci@ior.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Unit of Medical Oncology</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Mascarin, MD</last_name>
      <phone>+390434659</phone>
      <phone_ext>536</phone_ext>
      <email>mascarin@cro.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Mascarin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C. - Unit of Medical Oncology</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Aglietta, MD</last_name>
      <phone>+39.011.9933</phone>
      <phone_ext>628</phone_ext>
      <email>massimo.aglietta@ircc.it</email>
    </contact>
    <contact_backup>
      <last_name>Luisa Gioeni, Pharmacist</last_name>
      <phone>+39.011.9933</phone>
      <phone_ext>278</phone_ext>
      <email>luisa.gioeni@ircc.it</email>
    </contact_backup>
    <investigator>
      <last_name>Massimo Aglietta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Grignani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Sanitario Gradenigo</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Comandone, MD</last_name>
      <phone>+390118151</phone>
      <phone_ext>211</phone_ext>
      <email>alessandro.comandone@gradenigo.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Comandone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Ferrari, MD</last_name>
      <phone>+390516366</phone>
      <phone_ext>411</phone_ext>
      <email>stefano.ferrari@ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Emanuela Marchesi, PhD</last_name>
      <phone>+390516366</phone>
      <phone_ext>400</phone_ext>
      <email>emanuela.marchesi@ior.it</email>
    </contact_backup>
    <investigator>
      <last_name>Stefano Ferrari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico S. Orsola Malpighi di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcangelo Prete, MD</last_name>
      <phone>+390516363</phone>
      <phone_ext>111</phone_ext>
      <email>tmoped@aosp.bo.it</email>
    </contact>
    <investigator>
      <last_name>Arcangelo Prete, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servizio di Oncoematologi Pediatrica Ospedale microcitemico ASL 8</name>
      <address>
        <city>Cagliari</city>
        <zip>Rosamaria</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosamaria Mura, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rosamaria Mura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Tamburini, MD</last_name>
      <phone>+3905556</phone>
      <phone_ext>621</phone_ext>
      <email>a.tamburini@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Angela Tamburini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Garaventa, MD</last_name>
      <phone>+390105636</phone>
      <phone_ext>694</phone_ext>
      <email>albertogaraventa@ospedale-gaslini.ge.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Garaventa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FONDAZIONE IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Luksch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Luksch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianni Bisogno, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gianni Bisogno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Ferraresi, MD</last_name>
      <phone>+390652666</phone>
      <phone_ext>773</phone_ext>
      <email>ferraresi@ifo.it</email>
    </contact>
    <contact_backup>
      <last_name>, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Virginia Ferraresi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesu'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Cozza, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raffaele Cozza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
      <phone>+39.011.3135</phone>
      <phone_ext>230</phone_ext>
      <email>franca.fagioli@unito.it</email>
    </contact>
    <investigator>
      <last_name>Franca Fagioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>S. Ferrari, T. Alvegard, R. Luksch, A. Tienghi, K. S. Hall, G. Bernini, A. Brach del Prever, P. Picci, G. Bacci, S. Smeland Non-metastatic Ewing's family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. Preliminary results of the Italian/Scandinavian ISG/SSG III protocol. J Clini Oncol, 2007 ASCO Annual Meeting Proceedings Vol 25 (June 20 Suppl), 2007: 10014</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2013</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non metastatic Ewing's Sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Dactinomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

